| |
|
|
|
|
|
||||
|
|
|
|
|
|||||||
|
Shionogi USA in the News Shionogi acquires exclusive marketing and distribution rights for CEDAX® (ceftibuten) in the United States Osaka, Japan and Florham Park, New Jersey USA, August 27, 2004 -- Shionogi & Co., Ltd., a leading Japanese pharmaceutical company focused on the development and commercialization of novel therapeutics, has acquired exclusive marketing and distribution rights for CEDAX® (ceftibuten) in the United States, including Puerto Rico. Following a brief period of transition, Shionogi USA, Inc., a wholly-owned subsidiary of Shionogi & Co, Ltd., will begin marketing and distributing CEDAX®. Ownership of the CEDAX® NDA will also be transferred to Shionogi USA, Inc. Since it’s formation in 2001, Shionogi USA has focused primarily on advancing clinical development programs for novel therapeutics discovered by Shionogi & Co, Ltd.’s research laboratories in Japan. By obtaining exclusive marketing and distribution rights for CEDAX®, Shionogi USA has now expanded its infrastructure to support commercial activities. In promoting CEDAX®, Shionogi USA will utilize a contract sales force provided by PDI, Inc. The marketing and distribution of CEDAX® in the United States represents a significant milestone in Shionogi’s long-term globalization strategy. With the expansion of Shionogi USA, Inc., Shionogi & Co, Ltd. is building the infrastructure and expertise necessary to independently support the development and commercialization of pharmaceutical products in the United States. About Cedax: CEDAX®, a third generation cephalosporin antibiotic, was originally discovered by Shionogi & Co, Ltd. and licensed to Schering-Plough Corporation outside of Japan. The product received US NDA approval in 1995, and was most recently marketed and distributed in the United States by Biovail Pharmaceuticals Inc. CEDAX® is indicated for the treatment of acute exacerbations of chronic bronchitis, acute otitis media, and pharyngitis/tonsillitis. CEDAX® is a once a day medication available in capsules and a cherry-flavored suspension. Additional information on CEDAX® can be found at www.shionogiusa.com/cedax. For Further Information Contact:
|
||||||||
|
|
|||||||
